Praveen Kumar Marimuthu

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Praveen Kumar Marimuthu
May 29, 2025, 17:28 | Science
Praveen Kumar Marimuthu: RWD Shows NACT Plus Immunotherapy Nearly Doubles pCR in MIBC
Praveen Kumar Marimuthu, Assistant Professor of Medical Oncology at Christian Medical College and Hospital, shared…
May 20, 2025, 10:42 | Science
Praveen Kumar Marimuthu: Pharmacovigilance alert in NSCLC
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at the Christian Medical College and Hospital, shared…
May 16, 2025, 07:10 | Science
Praveen Kumar Marimuthu Highlights Benefits of Individualized Uterine Radiotherapy for Cervical Cancer
Praveen Kumar Marimuthu, [Title not provided] — shared on X: “Adding to the authors' points…
May 15, 2025, 15:08 | Science
Praveen Kumar Marimuthu: Preliminary Results with the Combo of Chemo, OMT and Low-Dose Nivo in Unresectable Oral Cancers
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at the Christian Medical College and Hospital, reshared…
May 13, 2025, 10:08 | Insight
Praveen Kumar Marimuthu: IMRT Not Better Than 3DCRT in RAPIDO
Praveen Kumar Marimuthu, Assistant Professor - Medical Oncology at Christian Medical College and Hospital, shared…
May 8, 2025, 17:11 | Insight
Praveen Kumar Marimuthu highlights EMBRACE II as a new standard of care for locally advanced cervical cancer
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at the Christian Medical College and Hospital,…
May 5, 2025, 11:04 | Blog
ESTRO25: What’s Happening on Day 3
As Day 3 of the ESTRO25 Congress unfolded in Vienna, the Austria Center buzzed with…
May 1, 2025, 09:14 | Science
Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an…
Apr 29, 2025, 09:47 | Science
Praveen Kumar Marimuthu: Neoadjuvant dostarlimab for Stage I–III dMMR solid tumors
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an…
Apr 28, 2025, 05:34 | Science
Benjamin Besse discussed de-escalation strategies in patient management and clinical trials at ELCC25
Praveen Kumar Marimuthu, Medical Oncologist at CMC Vellore, shared a post on LinkedIn: "Benjamin Besse…
Apr 14, 2025, 14:22 | Science
Praveen Kumar Marimuthu: Five-year overall survival update from the HIMALAYA study
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared a…
Apr 11, 2025, 08:49 | Blog
Praveen Kumar Marimuthu: Advancing Care in Recurrent Low-Grade Serous Ovarian Cancer
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital ,…
Apr 5, 2025, 14:07 | Blog
Praveen Kumar Marimuthu: Clinical outcomes of lung-only and liver-only metastatic pancreatic cancer
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared…
Apr 4, 2025, 17:22 | Insight
Sevinç Balli: Low dose Nivolumab maybe an option?
Sevinç Balli, Medical Oncologist at Ankara University, shared JCO Global Oncology's post on X: "Low…
Mar 26, 2025, 03:52 | Insight
Praveen Kumar Marimuthu: Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III NSCLC
Praveen Kumar Marimuthu, DM Resident - Medical oncology at Christian Medical College and Hospital, shared…
Aug 11, 2024, 19:47 | Blog
Praveen Kumar Marimuthu: Phase 2 trial Carboplatin, Pemetrexed, Cetuximab for advanced NSCLC
Praveen Kumar Marimuthu, Final year Medical Oncology Trainee at CMC Vellore, shared on X: "OPEN FOR…
All: 16 Posts: 1 - 100
Special Coverage